Products for Research Use Only

Balsalazide

CAT: 0804-HY-B0667-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0667-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Balsalazide is a prodrug of amino salicylic acid that releases mesalamine in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the IL-6/STAT3 pathway[1][2][3].
CAS Number
80573-04-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Interleukin Related; STAT
Type
Reference compound
Related Pathways
Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Balsalazide.html
Concentration
10mM
Purity
99.20
Solubility
1M NaOH : 50 mg/mL (ultrasonic; adjust pH to 12 with NaOH) |DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(O)C1=CC(/N=N/C2=CC=C(C(NCCC(O)=O)=O)C=C2)=CC=C1O
Molecular Formula
C17H15N3O6
Molecular Weight
357.32
Precautions
H302, H315, H319, H335
References & Citations
[1]Do EJ, et al. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. J Gastroenterol Hepatol. 2016 Aug;31 (8) :1453-61.|[2]Kruis W, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut, 2001. 49 (6) : p. 783-789.|[3]Seema A Patil, et al. Balsalazide disodium for the treatment of ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2008 Apr;2 (2) :177-84.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
IL-1; IL-6; STAT3